NCT00102297View on ClinicalTrials.gov

Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2005

Study Completion Date

June 30, 2007

Conditions
Diabetes Mellitus
Interventions
DRUG

FG-3019

Trial Locations (5)

22908

University of Virginia, Charlottesville

75231

Radiant Research, Dallas

78229

Diabetes & Glandular Disease, San Antonio

90502

UCLA - LA BioMed, Los Angeles

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Lead Sponsor

FibroGen
All Listed Sponsors
lead

FibroGen

INDUSTRY